AMG3969 is primarily utilized in medical research and drug development for cancer treatment, particularly targeting cancers with KRAS protein mutations, which are common in various types such as lung, pancreatic, and colorectal cancer. It is designed as a selective inhibitor to block the function of abnormal KRAS, thereby reducing the growth and spread of cancer cells. In addition to preclinical studies investigating its potential to inhibit tumor proliferation and understand mechanisms in oncology, AMG3969 is currently in clinical trials to assess its efficacy and safety in cancer patients. It is also used in combination with other therapeutic agents to evaluate synergistic effects. By providing insights into novel strategies against KRAS-driven cancers, AMG3969 plays a crucial role in advancing targeted therapies.